LGND vs. RGEN, HALO, MDGL, IONS, ALKS, BCRX, FOLD, CLDX, INVA, and MNKD
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.
Ligand Pharmaceuticals vs. Its Competitors
Ligand Pharmaceuticals (NASDAQ:LGND) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
Ligand Pharmaceuticals received 136 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 67.09% of users gave Repligen an outperform vote.
Ligand Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Ligand Pharmaceuticals has higher earnings, but lower revenue than Repligen. Repligen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Repligen. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 6 mentions for Repligen. Repligen's average media sentiment score of 1.37 beat Ligand Pharmaceuticals' score of 0.58 indicating that Repligen is being referred to more favorably in the news media.
Ligand Pharmaceuticals has a net margin of 29.68% compared to Repligen's net margin of -4.64%. Ligand Pharmaceuticals' return on equity of 4.95% beat Repligen's return on equity.
Ligand Pharmaceuticals currently has a consensus price target of $146.14, indicating a potential upside of 27.69%. Repligen has a consensus price target of $173.25, indicating a potential upside of 31.95%. Given Repligen's higher possible upside, analysts clearly believe Repligen is more favorable than Ligand Pharmaceuticals.
Summary
Ligand Pharmaceuticals beats Repligen on 11 of the 18 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LGND) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy LGND Stock Free LGND Stock Alerts